Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled AZD8871 in Healthy Male Subjects
NCT02814656Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of navafenterol in chronic obstructive pulmonary disease (COPD) and asthma (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Number of Participants With ≥1 Treatment Emergent Adverse Event in Any Category, Number of Participants With Clinically Relevant Abnormalities in Recording of Physical Examination and 7 more. Started Jun 2016; status: completed.
02
Drugs
navafenterol
03
Conditions
chronic obstructive pulmonary disease (COPD)asthma
Beyond the preview
Go deeper on NCT02814656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814656.